Monday 11 June 2018

Mumbai Angels Network Invests in Theranosis a Non-Invasive Cancer Diagnostic Company

                                                 


June 11, 2018: Mumbai Angels Network is pleased to announce our investment in  Theranosis Life Sciences, a medical diagnostic startup, that targets case-specific cancer diagnostic therapies as an alternative to conventional ‘one size fits all’ treatment.
Founded in 2016, Theranosis, based out of Hyderabad, India, is exploring non-invasive diagnostics for cancer patients. The company has a patented device that can reduce the need for surgical biopsies. Theranosis aspires to exhibit revolutionary innovations in the cancer treatment landscape.    
Theranosis is spearheading precision medicine in oncology in India and other developing countries. To implement the latest advances in companion diagnostics they have developed a patented microfluidics lab-on-a-chip device which detects circulating tumor cells from a simple blood sample of a cancer patient, circumventing the need for a surgical biopsy.
This procedure called liquid biopsy is a less invasive method and diminishes severe adverse effects triggered by chemotherapy. Another beneficial outcome is that it monitors treatment responses in real time.
Dr. Shibichakravarthy Kannan, Founder & CEO, has an impressive background which includes clinical research in HIV and TB, a PhD in Molecular Biology andBiochemistry, industry experience in liquid biopsy and a doctoral fellowship from the MD Anderson Centre, Houston, USA. Dr. Dharman, Co-Founder and Promoter, hails from the University Of Texas School Of Public Health, Houston, USA.
Shantanu Agarwal and Akshay Mittal, Deal Leads, Mumbai Angels Network said “It is a privilege to join Dr. Kannan and Dr. Dharman, along with their team, who have over 35 years of relevant experience and knowledge in the space to take things forward.  Together, we hope to achieve their vision to build a cutting-edge medical diagnostic and therapy firm that aids health care providers as well as patients all across the world”
Nandini Mansinghka, CEO and Managing Director , Mumbai Angels Network said “We  focus relentlessly on bringing unique, curated investment opportunities to our investor members within the network. Our investment in Thernosis highlights our focus on niche opportunities in the healthcare and healthtech space. Thernosis also fits very well in another of our key investment themes, that of Indian companies with the potential to expand into international markets”
Mumbai Angels Network is delighted to partner with Thernosis on its journey to develop what could be a ground breaking treatment.
_______________________________________________________________
About Mumbai Angels Network
Started in 2006, Mumbai Angels Network (The MA Network) is India’s premier investment platform focused on investments in new ventures. The MA Network is today 300+ members strong across 6 chapters (Mumbai, Delhi, Bangalore, Kolkata, Hyderabad and Pune). We have built a strong investment framework through which we showcase 60-70 highly curated investment opportunities to our memberbase, chosen from a funnel of 800-1000 companies we review every month. The network now has a 120+ strong portfolio with 30+ exits. several of whom were at multiples comparable with global benchmarks in new venture investing.

No comments:

Post a Comment